Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.91 +11.5%	$2.36	$1.42 ▼ $5.97	$40.66M	1.33	104,670 shs	28,763 shs
KPTI Karyopharm Therapeutics	$5.92 +27.3%	$4.35	$3.51 ▼ $16.95	$51.33M	0.28	148,374 shs	1.62 million shs
PLUR Pluri	$4.97 +2.7%	$4.98	$3.33 ▼ $7.13	$39.15M	0.76	8,471 shs	9,885 shs
PRTG Portage Biotech	$8.68 -1.4%	$6.46	$2.30 ▼ $23.01	$9.10M	0.24	46,079 shs	15,155 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	+6.20%	+15.48%	+45.50%	-35.76%
KPTI Karyopharm Therapeutics	0.00%	+50.25%	+45.45%	+11.28%	-51.16%
PLUR Pluri	0.00%	+4.61%	-8.13%	-4.61%	-10.29%
PRTG Portage Biotech	0.00%	-6.67%	+46.37%	+10.01%	+7,974.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.3664 of 5 stars	3.5	5.0	0.0	2.3	3.3	0.0
KPTI Karyopharm Therapeutics	3.864 of 5 stars	3.4	0.0	4.6	2.3	2.5	0.6
PLUR Pluri	2.252 of 5 stars	3.5	3.0	0.0	1.9	1.7	0.0
PRTG Portage Biotech	1.2739 of 5 stars	0.0	5.0	0.0	2.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$16.00	449.83% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	474.32% Upside
PLUR Pluri	3.00	Buy	$12.00	141.45% Upside
PRTG Portage Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRTG, PLUR, CALC, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
6/2/2025	PLUR Pluri	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.35	N/A	N/A	($27.55) per share	-0.21
PLUR Pluri	$330K	118.53	N/A	N/A	$1.00 per share	4.97
PRTG Portage Biotech	N/A	N/A	N/A	N/A	($0.79) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	9/17/2025 (Estimated)
PRTG Portage Biotech	-$6.77M	-$41.65	N/A	∞	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)

Latest PRTG, PLUR, CALC, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.39	5.45	5.66
KPTI Karyopharm Therapeutics	N/A	0.99	1.28
PLUR Pluri	51.65	4.81	4.81
PRTG Portage Biotech	N/A	2.02	2.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
KPTI Karyopharm Therapeutics	66.44%
PLUR Pluri	16.59%
PRTG Portage Biotech	13.36%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
KPTI Karyopharm Therapeutics	2.98%
PLUR Pluri	25.93%
PRTG Portage Biotech	42.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
PLUR Pluri	150	7.87 million	5.83 million	Optionable
PRTG Portage Biotech	6	1.05 million	608,000	Optionable

PRTG, PLUR, CALC, and KPTI Headlines

Recent News About These Companies

Portage Biotech (NASDAQ:PRTG) Stock Price Down 1.4% - Time to Sell?

August 16 at 3:49 AM | americanbankingnews.com

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

July 25, 2025 | globenewswire.com

Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | Nasdaq

June 27, 2025 | nasdaq.com

PRTG Portage Biotech Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Portage Biotech Inc. (PRTG) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Portage Biotech Regains Nasdaq Compliance

June 25, 2025 | tipranks.com

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

June 25, 2025 | globenewswire.com

Portage Biotech Inc. (PRTG) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Portage Biotech acquires stake in Compedica for $5 million

June 10, 2025 | investing.com

Portage Biotech and Compedica Forge Strategic Alliance with Stock Exchange

June 9, 2025 | tipranks.com

Portage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity Investment

June 9, 2025 | quiverquant.comQ

Portage Biotech and Compedica Stock-for-Stock Exchange

June 9, 2025 | globenewswire.com

Portage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human Trial

April 28, 2025 | marketwatch.com

Portage Biotech stock soars on promising preclinical results

April 28, 2025 | za.investing.com

Portage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More Bullish

April 28, 2025 | msn.com

Portage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025

April 28, 2025 | quiverquant.comQ

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

April 28, 2025 | globenewswire.com

Insider Stock Buying Reaches US$2.15m On Portage Biotech

April 26, 2025 | finance.yahoo.com

Portage Biotech Inc. Common Stock (PRTG) Pre-Market

March 30, 2025 | nasdaq.com

Portage Biotech presents preclinical data for PORT-7

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRTG, PLUR, CALC, and KPTI Company Descriptions

CalciMedica NASDAQ:CALC

$2.91 +0.30 (+11.49%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$2.88 -0.03 (-1.03%)

As of 08/15/2025 07:11 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Karyopharm Therapeutics NASDAQ:KPTI

$5.92 +1.27 (+27.31%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.68 -0.24 (-4.05%)

As of 08/15/2025 07:58 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Pluri NASDAQ:PLUR

$4.97 +0.13 (+2.69%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$4.42 -0.55 (-11.07%)

As of 08/15/2025 07:56 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Portage Biotech NASDAQ:PRTG

$8.68 -0.12 (-1.36%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.82 +0.15 (+1.67%)

As of 08/15/2025 07:52 PM Eastern

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time